These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24319210)

  • 1. Novel therapy for Hodgkin lymphoma.
    Batlevi CL; Younes A
    Hematology Am Soc Hematol Educ Program; 2013; 2013():394-9. PubMed ID: 24319210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.
    Schmitz R; Stanelle J; Hansmann ML; Küppers R
    Annu Rev Pathol; 2009; 4():151-74. PubMed ID: 19400691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
    Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
    J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetable molecular pathways in classical Hodgkin's lymphoma.
    Adams H; Obermann EC; Dirnhofer S; Tzankov A
    Expert Opin Investig Drugs; 2011 Feb; 20(2):141-51. PubMed ID: 21204722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
    Illés Á; Jóna Á; Miltényi Z
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents for the treatment of Hodgkin lymphoma.
    Dumaswala K; Mehta A
    Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years.
    Vassilakopoulos TP; Angelopoulou MK
    Semin Hematol; 2013 Jan; 50(1):4-14. PubMed ID: 23507479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB deregulation in Hodgkin lymphoma.
    Weniger MA; Küppers R
    Semin Cancer Biol; 2016 Aug; 39():32-9. PubMed ID: 27221964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin for the treatment of Hodgkin's lymphoma.
    Pham A; Chen R
    Expert Rev Hematol; 2015 Aug; 8(4):403-12. PubMed ID: 25967932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
    Younes A
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphomagenesis in Hodgkin lymphoma.
    Matsuki E; Younes A
    Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on emerging drugs for Hodgkin lymphoma.
    von Tresckow B; Diehl V
    Expert Opin Emerg Drugs; 2014 Jun; 19(2):215-24. PubMed ID: 24749769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
    Younes A; Ansell SM
    Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.
    Eichenauer DA; Engert A
    Eur J Haematol; 2014 Jul; 93(1):1-8. PubMed ID: 24750367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
    Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
    Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
    Carlo-Stella C; Santoro A
    Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
    Mottok A; Steidl C
    Blood; 2018 Apr; 131(15):1654-1665. PubMed ID: 29500175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.